EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

qHBsAg outperforms ALT/qHBsAg ratio in predicting HBsAg seroclearance after cessation of entecavir versus tenofovir

Hsing-Yun Lee, Cheng-Yuan Peng, Kwong-Ming Kee, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Sheng-Nan Lu, Chien-Hung Chen

Biomedical Journal · 2026

DOI: 10.1016/j.bj.2026.100945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Journal, 2026. Verfasst von Hsing-Yun Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medi…. Hauptthemen laut MEDLINE: Tenofovir, Guanine, Hepatitis B Surface Antigens, Hepatitis B, Chronic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital, Socialist Republic of Vietnam Ministry of Science and Technology, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We aimed to establish the optimal value of the alanine aminotransferase (ALT)/quantitative HBsAg (qHBsAg) ratio and qHBsAg level at end of treatment (EOT) to predict HBsAg seroclearance following cessation of entecavir versus tenofovir disoproxil fumarate (TDF) in HBeAg-negative with chronic hepatitis B (CHB) patients. MATERIAL AND METHODS: This retrospective cohort study included 715 HBeAg-negative patients without cirrhosis who had previously received entecavir (n = 438) or TDF (n = 277). RESULTS: The cumulative incidences of HBsAg seroclearance at 5 and 10 years after cessation of entecavir or TDF were 13.0 % and 33.8 %, respectively. Both a qHBsAg level

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirGuanineHepatitis B Surface AntigensHepatitis B, ChronicAlanine TransaminaseAntiviral AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedAdult

Stichwörter der Autor:innen

Akaike information criterionBayesian information criterionEntecavirHBsAgTenofovir

Substanzen

entecavirTenofovirGuanineHepatitis B Surface AntigensAlanine TransaminaseAntiviral Agents

Autor:innen und Institutionen

  • Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; School of Medicine, China Medical University, Taichung, Taiwan.
  • Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. Electronic address: mf6@cgmh.org.tw.

Förderung

  • Chang Gung Memorial Hospital
  • Socialist Republic of Vietnam Ministry of Science and Technology
  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Lee, H. Y., Peng, C. Y., Kee, K. M., Hu, T. H., Wang, J. H., Hung, C. H., Lu, S. N., & Chen, C. H. (2026). qHBsAg outperforms ALT/qHBsAg ratio in predicting HBsAg seroclearance after cessation of entecavir versus tenofovir. Biomedical Journal. https://doi.org/10.1016/j.bj.2026.100945

Vancouver

Lee HY, Peng CY, Kee KM, Hu TH, Wang JH, Hung CH, et al. qHBsAg outperforms ALT/qHBsAg ratio in predicting HBsAg seroclearance after cessation of entecavir versus tenofovir. Biomedical Journal. 2026. doi:10.1016/j.bj.2026.100945

BibTeX
@article{Lee2026,
  author = {Lee, Hsing-Yun and Peng, Cheng-Yuan and Kee, Kwong-Ming and Hu, Tsung-Hui and Wang, Jing-Houng and Hung, Chao-Hung and Lu, Sheng-Nan and Chen, Chien-Hung},
  title = {qHBsAg outperforms ALT/qHBsAg ratio in predicting HBsAg seroclearance after cessation of entecavir versus tenofovir},
  journal = {Biomedical Journal},
  year = {2026},
  doi = {10.1016/j.bj.2026.100945}
}
Kostenlos starten →